🇺🇸 FDA

Company profile · Sponsor

IONIS

IONIS PHARMACEUTICALS INC

IONS · NYSE pharma CARLSBAD, CA, USA
Pipeline
24
Drugs
2
Patents
8

Quick answer

IONIS (IONS) is a pharma company. headquartered in CARLSBAD, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker IONS
Exchange NYSE
Company type pharma
Headquarters CARLSBAD, CA, USA
SEC CIK 0000874015

Pipeline (24)

Search pipeline →

  1. Alicaforsen

    IONIS

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  2. Donidalorsen

    IONIS

    Hereditary Angioedema

    phase 3 small molecule active

    4 trials

  3. Donidalorsen

    IONIS

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  4. Eplontersen

    IONIS

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  5. Eplontersen

    IONIS

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    phase 3 small molecule active

    2 trials

  6. ION 682884, ION 682884

    IONIS

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  7. ION 682884, Placebo injection, 0.8 ml (is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in Water for Injection) for subcutaneous administration

    IONIS

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

    phase 3 small molecule active

    1 trial

  8. ION363

    IONIS

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  9. ION363, ION363, Artificial Cerebrospinal Fluid (aCSF) for Injection, 5.0 mL (Placebo)

    IONIS

    Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations

    phase 3 small molecule active

    1 trial

  10. ION582

    IONIS

    Angelman Syndrome

    phase 3 small molecule active

    2 trials

  11. ION582

    IONIS

    Angelman syndrome

    phase 3 small molecule active

    1 trial

  12. ISIS 3521

    IONIS

    Lung Cancer

    phase 3 mab completed

    1 trial

  13. ISIS 678354

    IONIS

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    1 trial

  14. ISIS 678354, ISIS 678354, ISIS 678354

    IONIS

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  15. ISIS 721744

    IONIS

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  16. ISIS 721744, ISIS 721744

    IONIS

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  17. Inotersen

    IONIS

    FAP

    phase 3 small molecule completed

    2 trials

  18. Inotersen

    IONIS

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule completed

    1 trial

  19. Mipomersen

    IONIS

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  20. Mipomersen sodium

    IONIS

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  21. Olezarsen

    IONIS

    Hypertriglyceridemia

    phase 3 small molecule completed

    2 trials

  22. Olezarsen

    IONIS

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    3 trials

  23. Olezarsen

    IONIS

    Severe Hypertriglyceridemia

    phase 3 small molecule active

    3 trials

  24. Placebo injection, 0.8 ml is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in water for injection (wfi) intended for subcutaneous injection, ISIS 678354

    IONIS

    Severe Hypertriglyceridemia.

    phase 3 small molecule active

    1 trial

Drugs (2)

Search drugs →

  1. donidalorsen sodium

    DAWNZERA (AUTOINJECTOR)

    SUBCUTANEOUS approved

  2. olezarsen sodium

    TRYNGOLZA (AUTOINJECTOR)

    SUBCUTANEOUS approved

Patents (8)

Search patents →

  1. US 12409188

    Modulators of HSD17B13 expression

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12410430

    Modulating apolipoprotein (A) expression

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12410225

    Modulation of dendritic cell lineages

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12364753

    CD8 binding agents

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12350285

    Compounds and methods for reducing ATXN3 expression

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12351614

    CLEC9A-based chimeric protein complexes

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12351633

    PD-1 and PD-L1 binding agents

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12343357

    Compositions and methods for modulating MECP2 expression

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is IONIS?

IONIS (IONS) is a pharma company. headquartered in CARLSBAD, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does IONIS sponsor?

We track 24 ClinicalTrials.gov-linked programs for IONIS, including Alicaforsen and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does IONIS company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.